SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, Dec. 30, 2020 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:


Boston Scientific Corporation (BSX)


Class Period: 4/24/2019 – 11/16/2020
Lead Plaintiff Motion Deadline: February 2, 2021
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bsx/  


Splunk Inc. (SPLK)


Class Period: 10/21/2020 – 12/2/2020
Lead Plaintiff Motion Deadline: February 2, 2021
SECURITIES FRAUD
To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-splk/  

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email ([email protected]), or via the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163



Histogen Announces Pricing of $14.0 Million Upsized Public Offering

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) — Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it has it has priced a public offering of an aggregate of 14,000,000 shares of common stock (or common stock equivalents offered through the issuance of pre-funded warrants), together with accompanying warrants to purchase up to an aggregate of 14,000,000 shares of common stock, at an effective public offering price of $1.00 per share and accompanying warrant. Each share of common stock (or common stock equivalent offered through the issuance of a pre-funded warrant) will be sold in the offering with one warrant to purchase one share of common stock. The warrants have an exercise price of $1.00 per share, are immediately exercisable, and expire five years following the date of issuance.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds of the offering are expected to be $14.0 million, prior to deducting placement agent’s fees and other estimated offering expenses payable by Histogen and assuming none of the warrants issued in the public offering are exercised for cash. The offering is expected to close on or about January 5, 2021, subject to the satisfaction of customary closing conditions.

Histogen intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include continued development of products for our CCM, hECM and HSC programs, further research and development, capital expenditures and general and administrative expenses.

The securities described above are being offered by Histogen pursuant to a registration statement on Form S-1 (File No. 333-251491) previously filed with and declared effective by the U.S. Securities and Exchange Commission (“SEC”) on December 30, 2020, and an additional registration statement on Form S-1 filed pursuant to Rule 462(b), which became automatically effective on December 30, 2020. The offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the preliminary prospectus and, when available, electronic copies of the final prospectus relating to the offering may be obtained for free by visiting the SEC’s website at www.sec.gov or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at [email protected] or by telephone at 646-975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Histogen

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss our ability to satisfy the closing conditions of the public offering and the timing of the closing, the use of proceeds, our future operations and our ability to successfully initiate and complete clinical trials, obtain clinical trial data, and achieve regulatory milestones and related timing, including those related to the approval of the HST-003 IND and planned Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee, the reporting of week 26 study data for the ongoing HST-001 Phase 1a/2b trial for androgenic alopecia in men and the planned Phase 1 study of emricasan for the treatment of COVID-19; the nature, strategy and focus of our business; the sufficiency of our cash resources and ability to achieve value for our stockholders; and the development and commercial potential and potential benefits of any of our product candidates. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of ours that could differ materially from those described in or implied by the statements in this press release, including: market and other conditions, the uncertainties associated with the clinical development and regulatory approval of our product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier clinical trials and studies of our product candidates may not be predictive of future results; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase its costs and expenses; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including those risks discussed in our filings with the Securities and Exchange Commission. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.

Contact:

Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
[email protected]



Asetek A/S Announces Transactions Carried Out Under the Current Share Buyback Programme in Accordance With the “Safe Harbour Method”

PR Newswire

OSLO, Norway, Dec. 31, 2020 /PRNewswire/ — On October 23, 2020, Asetek A/S launched a share buyback programme, as described in company announcement of October 23, 2020. According to the programme, Asetek A/S will in the period until March 5, 2021 buy back own shares up to a maximum value of USD 4 million and with a maximum of 381,000 shares. The share buyback programme will be implemented in accordance with Regulation (EU) no. 596/2014 of 16th April 2014 of the European Parliament and Council and ommission Delegated Regulation (EU) no. 2016/1052, also referred to as the Safe Harbour rules.

                                   

Trading day

Number of shares bought back

                                   

Average purchase price (NOK)

   Amount (USD)              

                                   


Total, latest announcement

163,414

 

88.2272

 

 

1,594,538.23

                                   

42:

21 December 2020

 

3,404

 

102.5580

 

 

40,182.27

                                   

43:

                                   

22 December 2020

 

3,979

 

103.7518

 

47,392.70

                                   

44:

                                   

23 December 2020

 

3,112

 

103.6199

 

 

37,244.72

                                   

Total accumulated over week 52/2020

10,495

 

103.3255

 

124,819.69

                                   


Total accumulated during the


share buy-back programme

173,909

 

89.1383

 

 

1,719,357.92

 

With the transactions stated above, the Company owns a total of 1,008,156 shares as treasury shares, corresponding to 3.81% of the share capital. See the enclosure for information about the individual transactions made under the share buyback programme.

About Asetek

Asetek is the global leader in liquid cooling solutions for gaming and enthusiast PCs, data centers and servers. Founded in 2000, Asetek is headquartered in Denmark and has operations in California, Texas, China and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASTK.OL).

www.asetek.com

For further information, please contact:

Peter Dam Madsen, Chief Financial Officer
Mobile: +45 2080 7200, e-mail: [email protected]

Asetek A/S
Assensvej 2
DK-9220 Aalborg East
Denmark

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/asetek/r/asetek-a-s-announces-transactions-carried-out-under-the-current-share-buyback-programme-in-accordanc,c3263133

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/asetek-as-announces-transactions-carried-out-under-the-current-share-buyback-programme-in-accordance-with-the-safe-harbour-method-301199565.html

SOURCE Asetek

SDRL – Seadrill Announces Forbearance Agreement

PR Newswire

HAMILTON, Bermuda, Dec. 31, 2020 /PRNewswire/ — Seadrill Limited (“Seadrill” or the “Company”) (OSE: SDRL) (OTCQX: SDRLF) announces that it has entered into a forbearance agreement with certain creditors in respect of nine out of the group’s twelve senior secured credit facility agreements.

The purpose of the forbearance agreement is to allow the Company and its stakeholders more time to finalise negotiations on the head terms of a comprehensive restructuring of its balance sheet. Such a restructuring may involve the use of a court-supervised process. The Company continues to evaluate capital structure proposals from its financial stakeholders; whilst no agreement has been reached at this point it is expected that potential solutions will lead to significant equitization of debt which is likely to result in minimal or no recovery for current shareholders.

Pursuant to the forbearance agreement, the consenting creditors have agreed not to exercise any voting rights to, or otherwise take actions, in respect of certain events of default that may arise under those senior secured credit facility agreements as a result of the group not making certain interest payments, until and including the earlier of 29 January 2021 and any termination of the forbearance agreement.

Forbearance has not yet been agreed with respect to certain events of default or termination events that may arise under the three remaining senior secured credit agreements, the Company’s New Secured Notes, leasing arrangements for the West Hercules, West Linus and West Taurus and a bilateral guarantee facility with Danske Bank. Without a forbearance in respect of these arrangements, a non-payment of interest or other amounts due under the senior secured credit agreements, the Company’s New Secured Notes and/or the leasing arrangements could result in the creditors under these arrangements having the right to accelerate or otherwise enforce their rights under them.

FORWARD LOOKING STATEMENTS

This news release includes forward looking statements. Such statements are generally not historical in nature, and specifically include statements about the Company’s plans, strategies, business prospects, changes and trends in its business, the markets in which it operates and its restructuring efforts. These statements are made based upon management’s current plans, expectations, assumptions and beliefs concerning future events impacting the Company and therefore involve a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, which speak only as of the date of this news release. Consequently, no forward-looking statement can be guaranteed. When considering these forward-looking statements, you should keep in mind the risks described from time to time in the Company’s regulatory filings and periodical reporting. The Company undertakes no obligation to update any forward looking statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for the Company to predict all of these factors. Further, the Company cannot assess the impact of each such factor on its business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward looking statement.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Media questions should be directed to:

Iain Cracknell              
Director of Communications                 
+44 (0)7765 221 812

Analyst questions should be directed to:

Hawthorn Advisors       
[email protected]            
+44 (0)203 7454960

CONTACT:

[email protected] 
020 3745 4960

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/seadrill-limited/r/sdrl—seadrill-announces-forbearance-agreement,c3263118

Cision View original content:http://www.prnewswire.com/news-releases/sdrl—seadrill-announces-forbearance-agreement-301199564.html

SOURCE Seadrill Limited

Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate

PR Newswire

STOCKHOLM, Dec. 31, 2020 /PRNewswire/ — Eurocine Vaccines AB (“Eurocine Vaccines” or the “Company”) has today selected Biovian Oy, Turku, Finland, (“Biovian”) as the contract developer for the Company’s vaccine candidate against chlamydia. Biovian, which is an internationally recognized contract developer and manufacturer with its own GMP facility, will develop an industrial manufacturing method as well as manufacture study products for Eurocine Vaccines’ future studies, such as toxicological and clinical studies.

The collaboration for the development of a manufacturing method and preparations to produce the first batches will begin directly in the new year 2021 under the agreement signed today and includes activities at a total cost of appr. SEK 9.5 million (EUR 0.94 million). The costs fall within the Company’s budget for the chlamydia project. The work is within one of the prioritized areas that constitute Eurocine Vaccines’ key competencies. The collaboration signed today with Biovian covers activities initially lasting until November 2021. The mutual intention is to continue the collaboration until the project is completed.

CEO Hans Arwidsson comments

“Both we and Biovian are looking forward to the collaboration and the mutual knowledge transfer within biological pharmaceutical production, which is a highly intense area in the development of new pharmaceuticals. The selection of Biovian means that we can conduct our activities with continuity, since they also have their own GMP facility for the manufacture of products for clinical studies.”

This information is such information that Eurocine Vaccines AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person set out above, for publication on 30 December 2020.

CONTACT:

Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
[email protected] 
+46 70 634 0171

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eurocine-vaccines/r/eurocine-vaccines-has-selected-biovian-as-contract-developer-for-the-chlamydia-vaccine-candidate,c3263137

The following files are available for download:


https://mb.cision.com/Main/11552/3263137/1355297.pdf

Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate

Cision View original content:http://www.prnewswire.com/news-releases/eurocine-vaccines-has-selected-biovian-as-contract-developer-for-the-chlamydia-vaccine-candidate-301199563.html

SOURCE Eurocine Vaccines

Sonesta International Hotels Corporation To Acquire RLH Corporation, Creating One Of The World’s Largest Hotel Companies With Diversified Brands Across Multiple Market Segments

Adds More Than 900 Hotels to Sonesta

Accelerates Sonesta’s Hotel Franchising Capabilities

Industry Veteran Keith Pierce to Lead Sonesta Franchising and Development

PR Newswire

NEWTON, Mass., Dec. 30, 2020 /PRNewswire/ — Sonesta International Hotels Corporation (Sonesta) today announced that it has entered into a definitive agreement to acquire RLH Corporation (NYSE: RLH). RLH is the 10th-largest U.S.-based hotel franchise company with more than 900 hotels. After the closing of the transaction, Sonesta will become one of the largest hotel companies in the U.S. with approximately 1,200 hotels in diversified brands across multiple market segments. Sonesta also announced that upon closing of this transaction, 35-year hotel industry veteran Keith Pierce will be joining Sonesta as Executive Vice President, President of Franchise & Development.

Carlos Flores, President and Chief Executive Officer of Sonesta, made the following statement regarding today’s announcement:

“Sonesta started 2020 as a manager of 58 hotels under three Sonesta-specific brands in the U.S. Upon the completion of hotel conversions previously announced and the acquisition of RLH, Sonesta will become one of the largest hotel companies in the U.S., with approximately 1,200 hotels under a diverse set of 13 brands in multiple market segments. Whereas all of Sonesta’s hotels in the U.S. are currently self-managed, the acquisition of RLH significantly accelerates Sonesta’s hotel franchising capabilities by adding a franchise platform with more than 900 hotels. With the addition of Keith to our leadership team, we also have an experienced executive ready to manage the RLH business upon closing this transaction and we are well positioned to grow Sonesta’s franchising business in the future.”

Keith Pierce joins Sonesta with more than 35 years’ experience across the hospitality industry. He served most recently as President and Managing Partner of the Passionality Group, a hospitality investment and management advisory firm. Prior to that, he worked at Wyndham Worldwide, where he was Executive Vice President, Brand Operations for North America, and before that, President of Hotel Brand Operations for the Americas, and Group President for Hotels at Wyndham’s predecessor company, Cendant Corporation.

Keith Pierce made the following statement regarding today’s announcement:

“I am looking forward to welcoming RLH franchisees to Sonesta at this dynamic and promising moment in the company’s growth. I also look forward to working closely with the RLH franchising community and building on the strong foundation RLH has created. I believe Sonesta is currently one of the industry’s most exciting, forward-looking hotel companies. I look forward to helping propel the growth of Sonesta and working closely with the leadership team to continue building a world class hotel company.”

The acquisition of RLH is currently expected to close in the first half of 2021 and it is subject to customary closing conditions, including the approval of RLH’s shareholders. Sonesta expects to fund this transaction with cash-on-hand and/or through capital contributions from its shareholders. Hunton Andrews Kurth LLP is serving as legal counsel to Sonesta for this transaction.

About Sonesta

Sonesta is one of the fastest growing hospitality companies in the U.S., celebrating an approximate 350% increase in its managed hotel portfolio. Not including the transaction announced today, you will soon find nearly 300 Sonesta branded hotels across seven brands operating in the U.S., Canada, Chile, Colombia, Ecuador, Egypt, Peru, and St. Maarten. Discover Sonesta hotels, resorts, and suites in many of the most traveled U.S. destinations, including Atlanta, Austin, Boston, Chicago, Hilton Head, Houston, Los Angeles, Miami, New Orleans, Philadelphia, Portland, San Francisco, San Jose, San Juan, Seattle, St. Louis, and Washington D.C. For more about Sonesta and its locations, visit Sonesta.com or call +1.617.315.9200 or 800.Sonesta (800.766.3782) in the U.S. and Canada. Follow us on social media @SonestaHotels.

* High-resolution images are available at www.sonesta.com/media for all Sonesta hotels.

Media Contacts:
 

Lorie Juliano

[email protected]
office: 617.421.5429
mobile: 508.843.3769

Michael Frenkel

[email protected]

(201) 317-7035

 

Cision View original content:http://www.prnewswire.com/news-releases/sonesta-international-hotels-corporation-to-acquire-rlh-corporation-creating-one-of-the-worlds-largest-hotel-companies-with-diversified-brands-across-multiple-market-segments-301199562.html

SOURCE Sonesta International Hotels Corporation

SBA Extends COVID-19 Economic Injury Disaster Loan Application Deadline through Dec. 31, 2021

Washington, Dec. 30, 2020 (GLOBE NEWSWIRE) — The U.S. Small Business Administration today announced that the deadline to apply for the Economic Injury Disaster Loan (EIDL) program for the COVID-19 Pandemic disaster declaration is extended to Dec. 31, 2021.  The deadline extension comes as a result of the recent bipartisan COVID-19 relief bill passed by Congress and enacted by President Trump on Dec. 27, 2020. 

To date, the SBA has approved $197 billion in low-interest loans which provides working capital funds to small businesses, non-profits and agricultural businesses to make it through this challenging time.  

“Following the President’s declaration of the COVID-19 Pandemic, the SBA has approved over 3.6 million loans through our Economic Injury Disaster Loan program nationwide,” Administrator Jovita Carranza said. “The EIDL program has assisted millions of small businesses, including non-profit organizations, sole proprietors and independent contractors, from a wide array of industries and business sectors, to survive this very difficult economic environment.” 

EIDL loan applications will continue to be accepted through December 2021, pending the availability of funds. Loans are offered at very affordable terms, with a 3.75% interest rate for small businesses and 2.75% interest rate for nonprofit organizations, a 30-year maturity, and an automatic deferment of one year before monthly payments begin. Every eligible small business and nonprofit are encouraged to apply to get the resources they need.

### 

About the U.S. Small Business Administration

The U.S. Small Business Administration makes the American dream of business ownership a reality. As the only go-to resource and voice for small businesses backed by the strength of the federal government, the SBA empowers entrepreneurs and small business owners with the resources and support they need to start, grow or expand their businesses, or recover from a declared disaster. It delivers services through an extensive network of SBA field offices and partnerships with public and private organizations. To learn more, visit https://www.sba.gov.



Press Office
United States Small Business Administration
[email protected]

CEMATRIX Grants Incentive Options to Executive Officer

CALGARY, Alberta, Dec. 30, 2020 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSXV: CVX) (the “Corporation”) granted incentive stock options to an Executive Officer of the Corporation, pursuant to the Corporation’s Stock Option Plan, on December 29, 2020 for the purchase of a total of 250,000 common shares at an exercise price of $0.59 per share, at any time up to and including December 29, 2025.

ABOUT CEMATRIX

CEMATRIX is a rapidly growing, cash flow positive company that manufactures and supplies technologically advanced cellular concrete products developed from proprietary formulations across North America. This unique cement-based material with superior thermal protection delivers cost-effective, innovative solutions to a broad range of problems facing the infrastructure, industrial (including oil and gas) and commercial markets. Through recent acquisitions of Chicago based MixOnSite and Bellingham based Pacific International Grout, CEMATRIX is now North America’s largest Cellular Concrete company.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Jeff Kendrick – President and Chief Executive Officer
Phone: (403) 219-0484

Glen Akselrod – President, Bristol Capital
Phone: (905) 326 1888 ext 1
[email protected]

Jeff Walker, The Howard Group – Investor Relations
Phone: (888) 221-0915 or (403) 221-0915
[email protected]

Forward-looking information: This news release contains certain information that is forward looking and is subject to important risks and uncertainties (such statements are usually accompanied by words such as “anticipate”, expect”, “would’ or other similar words). Forward looking statements in this document are intended to provide CEMATRIX security holders and potential investors with information regarding CEMATRIX and its subsidiaries’ future financial and operations plans and outlook. All forward looking statements reflect CEMATRIX’s beliefs and assumptions based on information available at the time the statements were made. Readers are cautioned not to place undue reliance on this forward looking information. CEMATRIX undertakes no obligation to update or revise forward looking information except as required by law. For additional information on the assumptions made and the risks and uncertainties which may cause actual results to differ from the anticipated results, refer the CEMATRIX’s Management Discussion and Analysis dated April 27, 2020 under CEMATRIX’s profile on SEDAR at


www.sedar.com


and other reports filed by CEMATRIX with Canadian securities regulators.



SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Harvest Capital Credit Corp. – HCAP

PR Newswire

NEW YORK, Dec. 30, 2020 /PRNewswire/ — Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Harvest Capital Credit Corp. (“Harvest” or the “Company”) (HCAP) relating to its proposed acquisition by Portman Ridge Finance Corporation. Under the terms of the agreement, Harvest shareholders will receive a combination of cash and Portman common stock per share.

The investigation focuses on whether Harvest Capital Credit Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether and by how much this proposed transaction undervalues the Company.

Click here for more information:
 

https://www.monteverdelaw.com/case/harvest-capital-credit-corp

.
It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.   We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions.  Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in Harvest Capital Credit Corp. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde–associates-pc-announces-an-investigation-of-harvest-capital-credit-corp—hcap-301199560.html

SOURCE Monteverde & Associates PC

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRGX Global, Inc. – PRGX

PR Newswire

NEW YORK, Dec. 30, 2020 /PRNewswire/ —


Juan Monteverde
, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating PRGX Global, Inc. (“PRGX” or the “Company”) (PRGX) relating to its proposed acquisition by Adrian, a French private equity firm. Under the terms of the agreement, PRGX shareholders will receive $7.71 in cash per share.

The investigation focuses on whether PRGX Global, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether and by how much this proposed transaction undervalues the Company.

Click here for more information:
 

https://www.monteverdelaw.com/case/prgx-global-inc.

 
It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.   We were listed in the Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions.  Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in PRGX Global, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde–associates-pc-announces-an-investigation-of-prgx-global-inc–prgx-301199559.html

SOURCE Monteverde & Associates PC